Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Employees - 528, CEO - William J. Sibold, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): 8.6, Piotroski Score(max is 10): 2, Working Capital: $844048000, Total Assets: $1227327000, Retained Earnings: $-2184857000, EBIT: -282606000, Total Liabilities: $683873000, Revenue: $1132490000

AryaFin Target Price - $1308.03 - Current Price $ - Analyst Target Price $